Table 1 Demographic and clinical characteristics of patients at baseline
From: Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials
Total (N = 1937) | |||
|---|---|---|---|
Trial 1 (N = 1118) | Trial 2 (N = 819) | ||
N (%) | N (%) | N (%) | |
Age | |||
Mean (SD) | 68.68 (6.47) | 69.39 (5.75) | 68.98 (6.18) |
Median | 69 | 70 | 70 |
Q1-Q3 | 64–73 | 66–74 | 65–74 |
N (%) | |||
Performance status | |||
0 | 936 (83.7) | 721 (88) | 1657 (85.5) |
1 | 156 (14) | 96 (11.7) | 252 (13) |
2 | 17 (1.5) | 2 (0.2) | 19 (1) |
Unknown | 9 (0.8) | 0 (0) | 9 (0.5) |
Chronic disease | |||
None | 686 (61.4) | 321 (39.2) | 1007 (52) |
Cardiovascular only | 258 (23.1) | 214 (26.1) | 472 (24.4) |
Other or multiple | 165 (14.8) | 284 (34.7) | 449 (23.2) |
Unknown | 9 (0.8) | 0 (0) | 9 (0.5) |
Country | |||
Netherlands | 609 (54.5) | 260 (31.7) | 869 (44.9) |
France | 143 (12.8) | 199 (24.3) | 342 (17.7) |
Belgium | 98 (8.8) | 23 (2.8) | 121 (6.2) |
United Kingdom | 29 (2.6) | 86 (10.5) | 115 (5.9) |
Spain | 43 (3.8) | 59 (7.2) | 102 (5.3) |
Israel | 46 (4.1) | 15 (1.8) | 61 (3.1) |
Cyprus | 0 (0) | 58 (7.1) | 58 (3) |
Italy | 33 (3) | 24 (2.9) | 57 (2.9) |
Switzerland | 26 (2.3) | 23 (2.8) | 49 (2.5) |
Ireland | 0 (0) | 38 (4.6) | 38 (2) |
Turkey | 35 (3.1) | 0 (0) | 35 (1.8) |
Russia | 28 (2.5) | 0 (0) | 28 (1.4) |
Malta | 27 (2.4) | 0 (0) | 27 (1.4) |
Germany | 0 (0) | 14 (1.7) | 14 (0.7) |
Czech Republic | 0 (0) | 7 (0.9) | 7 (0.4) |
Poland | 0 (0) | 7 (0.9) | 7 (0.4) |
Luxembourg | 0 (0) | 6 (0.7) | 6 (0.3) |
Bosnia and Herzegovina | 1 (0.1) | 0 (0) | 1 (0.1) |